Nicholas D. James, PhD, MBBS, on Bladder Cancer: Cetuximab With Chemoradiotherapy
2020 Genitourinary Cancers Symposium
Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research in London, discusses results from a phase I/II feasibility study that showed the combination of cetuximab, chemoradiation, fluorouracil, and mitomycin yields high bladder cancer control rates with acceptable toxicity and quality of life, meriting further evaluation in a randomized trial (Abstract 491).
The ASCO Post Staff
Julie N. Graff, MD, of Oregon Health & Science University and Knight Cancer Institute, discusses study findings that show pembrolizumab plus enzalutamide after progression on enzalutamide produced clinical activity and can lead to durable responses, with a manageable safety profile. The phase III KEYNOTE-641 trial will test patients who are enzalutamide-naive (Abstract 15).
The ASCO Post Staff
Ziad Bakouny, MD, of Dana-Farber Cancer Institute, discusses two types of renal cell cancer that are associated with poor prognosis. Because recent early data suggest these tumors respond well to immune checkpoint inhibitors, the authors characterized the tumors in an integrative molecular and clinical study (Abstract 715).
The ASCO Post Staff
David P. Dearnaley, MD, of The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, discusses 8-year outcomes of the phase III CHHiP trial, which showed that modest hypofractionation is noninferior to conventional fractionation in localized prostate cancer, with no increase in side effects. Disease control was also reported in patients older than age 75 (Abstract 325).
The ASCO Post Staff
Syed A. Hussain, MD, of the University of Sheffield, discusses phase II findings comparing nintedanib or placebo in combination with gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer. The data showed that adding nintedanib was safe and well tolerated, with a significant improvement in progression-free and overall survival at 1 and 2 years (Abstract 438).
The ASCO Post Staff
Nicholas D. James, PhD, MBBS, of The Institute of Cancer Research in London, discusses the health economics of adding abiraterone to first-line, long-term hormone therapy in prostate cancer, and what it means for long-term survival, quality-adjusted survival, and cost-effectiveness (Abstract 204).
